A synthetic lipopolysaccharide-binding peptide based on amino acids 27- 39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood

Journal of Immunology

Volumn 161, Issue 7, 1998, Pages 3607-3615

  De Haas, Carla J C ^a   Van Der Tol, Marijke E ^a   Van Kessel, Kok P M ^a   Verhoef, Jan ^a   Van Strijp, Jos A G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID P COMPONENT; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY;

AMINO ACID SYNTHESIS; ARTICLE; BINDING AFFINITY; BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN CELL; NEUTROPHIL; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; SALMONELLA MINNESOTA;

EID: 0032193238     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Haziot, A., S. Chen, E. Ferrero, M. G. Low, R. Silber, and S. M. Goyert. 1988. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol. 141:547.
2. Wright, S. D., R. A. Ramos, A. Hermanowski Vosatka, P. Rockwell, and P. A. Detmers. 1991. Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14. J. Exp. Med. 173:1281.
3. Pugin, J., C. C. Schurer Maly, D. Leturcq. A. Moriarty, R. J. Ulevitch, and P. S. Tobias. 1993. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 90:2744.
4. Yu, B., and S. D. Wright. 1996. Catalytic properties of lipopolysaccharide (LPS) binding protein: transfer of LPS to soluble CD14. J. Biol. Chem. 271:4100.
5. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457.
6. Wurfel, M. M., S. T. Kunitake, H. Lichenstein, J. P. Kane, and S. D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180:1025.
7. Parker, T. S., D. M. Levine, J. C. Chang, J. Laxer, C. C. Coffin, and A. L. Rubin. 1995. Reconstituted high-density lipoprotein neutralizes Gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63:253.
8. Cowland, J. B., A. H. Johnsen, and N. Borregaard. 1995. hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett. 368:173.
9. 2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Invest. 90:1122.
10. Marra. M. N., C. G. Wilde, M. S. Collins, J. L. Snable, M. B. Thornton, and R. W. Scott. 1992. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J. Immunol. 148:532.
11. Ohno, N., and D. C. Morrison. 1989. Lipopolysaccharide interaction with lysozyme: binding of lipopolysaccharide to lysozyme and inhibition of lysozyme enzymatic activity. J. Biol. Chem. 264:4434.
12. Wang, D., K. M. Pabst, Y. Aida, and M. J. Pabst. 1995. Lipopolysaccharide-inactivating activity of neutrophils is due to lactoferrin. J. Leukocyte Biol. 57:865.
13. Kalaria, R. N., P. G. Galloway, and G. Perry. 1991. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol. Appl. Neurobiol. 17:189.